Cargando…
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2) protein, mainly as a result of gene amplification. The receptor tyrosine kinase is believed to play a critical role in the pathogenesis and further proliferation of these tumors. The application of trastu...
Autor principal: | Mukohara, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263614/ https://www.ncbi.nlm.nih.gov/pubmed/22295205 http://dx.doi.org/10.1155/2011/730360 |
Ejemplares similares
-
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015) -
Optimizing (neo)adjuvant treatment of HER2-positive breast
cancer
por: Basho, Reva K., et al.
Publicado: (2018) -
PI3K mutations in breast cancer: prognostic and therapeutic implications
por: Mukohara, Toru
Publicado: (2015) -
Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009) -
How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)